Nectar Lifesciences

LifeSci Partners Expands Presence in Asia Pacific with Appointment of Jeff Seo

Retrieved on: 
Tuesday, September 12, 2023
Organizational founder, Senior, Partner, Ernst & Young, Business, Wall Street, Nectar Lifesciences, Macquarie Group, Maybank, Ernst, CPA, Standard Chartered, Management

NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- LifeSci Partners, the leading provider of strategic advisory services to the global healthcare sector, today announced the continued expansion of its capital markets advisory leadership team in Asia with the appointment of Jeff Seo as Managing Director and Head of the APAC Region for LifeSci Partners and LifeSci Venture Partners.

Key Points: 
  • NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- LifeSci Partners, the leading provider of strategic advisory services to the global healthcare sector, today announced the continued expansion of its capital markets advisory leadership team in Asia with the appointment of Jeff Seo as Managing Director and Head of the APAC Region for LifeSci Partners and LifeSci Venture Partners.
  • “LifeSci Partners is the leading provider of healthcare advisory services, with a strong presence in the U.S., Europe and Israel.
  • “We are very pleased to appoint Jeff Seo to this leadership role.
  • His responsibilities will include establishing relationships with healthcare innovators in APAC and identifying investment opportunities for LifeSci Venture Partners.

Bonerge Lifescience opened its new manufacturing facility to further support the innovation of its branded ingredients

Retrieved on: 
Sunday, August 13, 2023
Other Health, Seniors, Consumer, Health, Fitness & Nutrition, CNAS, ISO, National Organic Program, HPLC, ISO 17025, Nectar Lifesciences, GAP, CGMP, Halal, LC-MS, ICP-MS, HACCP, Safety, Fine chemical, Kashrut

The new factory is focusing on manufacturing innovative plant extracts including BefisetinTM, Bonerge’s branded fisetin ingredient.

Key Points: 
  • The new factory is focusing on manufacturing innovative plant extracts including BefisetinTM, Bonerge’s branded fisetin ingredient.
  • This strategic production expansion accelerates the development of Bonerge’s existing and upcoming branded ingredients.
  • “The new manufacturing facility is one of the cornerstones for us to elevate our products, enabling the company to bring more innovative branded ingredients to the market,” said Allen Ge, CEO of Bonerge Lifescience.
  • Bonerge’s new state-of-the-art, 70,000-square-meter manufacturing facility is located in Hunan, China.

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

Retrieved on: 
Friday, December 16, 2022
Nectar Lifesciences, TSC, WHEN, Diffusion, Innisfree, AND, Proxy statement, Suite, GBM, Annual general meeting, Beneficial ownership, NUALS Arts and Literary Annual Meet, Name, Attention, Proxy, Annual, Corporation, Oxygen, Hypoxia, Tissue, Security (finance), Shareholder

CHARLOTTESVILLE, Va., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd., affiliated entities and certain related parties (collectively, “LifeSci Special Opportunities”), with respect to, among other things, the membership and composition of the Company’s board of directors (the “Board”), before the Company’s 2022 Annual Meeting of Stockholders (the “Annual Meeting”).

Key Points: 
  • Under the terms of the agreement, LifeSci Special Opportunities will withdraw its slate of director nominees (the “LifeSci Nominees”) previously nominated for election and vote in favor of the Board’s recommended nominees at the Annual Meeting.
  • “We appreciate LifeSci Special Opportunities’ support of our process.”
    LifeSci Special Opportunities will not be submitting blue proxy cards for tabulation for the Annual Meeting and encourages stockholders to submit a WHITE proxy card in support of the Board’s recommendations on each proposal.
  • LifeSci Special Opportunities, which currently beneficially owns approximately 4.8% of Diffusion’s outstanding shares, in the aggregate, is also subject to certain customary standstill provisions under the terms of the agreement.
  • The complete agreement between Diffusion and LifeSci Special Opportunities will be filed on a Form 8-K with the U.S. Securities and Exchange Commission.

Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing

Retrieved on: 
Monday, December 5, 2022
Acquisition, Annual report, Science, Sale, Dechert, Chairperson, Annual general meeting, Consultant, Eastern Time Zone, Oxygen, COVID-19, Roman Catholic Diocese of La Crosse, TSC, Food, Cancer, ZERO, Regulation of tobacco by the U.S. Food and Drug Administration, Lobbying, NUALS Arts and Literary Annual Meet, Knowledge, Our Boarding House, ALL, Innisfree, CFO, GBM, Negotiation, Exercise, Science 37, SPAC, Tissue, Nectar Lifesciences, Particular, Letter, Confusion, Hypoxia, Auction, Retail, Fine chemical, Holding company, Security (finance), Risk management, Management, Financial services, Cryptocurrency, Airline, Real estate, Pharmaceutical industry, Ammunition, Shareholder, Diffusion

The letter highlights the strength, experience and quality of the Company’s board of directors as it continues to take steps to unlock stockholder value through a strategic review process.

Key Points: 
  • The letter highlights the strength, experience and quality of the Company’s board of directors as it continues to take steps to unlock stockholder value through a strategic review process.
  • Diffusion’s board of directors urges stockholders to vote “FOR” each of its six nominees for director on your WHITE proxy card.
  • Our Board has made significant progress to date in its strategic review of opportunities to enhance value for all stockholders.
  • Our Board is currently composed of uniquely qualified leaders with public company senior leadership experience, including at the C-level in Fortune 50 companies.

Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process

Retrieved on: 
Monday, November 14, 2022
Nectar Lifesciences, Sale, Hypoxia, Oxygen, Diffusion, Control, Exercise, GBM, Annual general meeting, TSC, Cancer, Particular, Glioblastoma, Tissue, Regulation of tobacco by the U.S. Food and Drug Administration, Annual report, COVID-19, Dechert, Food, Patient, Investment banking, Renewable energy, Medical imaging, Fine chemical, Pharmaceutical industry

The Company has made significant progress since publicly announcing the strategic review process less than three weeks ago, building upon efforts over the course of the past year to identify a potential strategic transaction that will enhance value for Diffusion stockholders in this period of challenging market conditions.

Key Points: 
  • The Company has made significant progress since publicly announcing the strategic review process less than three weeks ago, building upon efforts over the course of the past year to identify a potential strategic transaction that will enhance value for Diffusion stockholders in this period of challenging market conditions.
  • While the Company cannot provide any assurance as to the ultimate outcome of this strategic review process, the Company reports that it is in the active bidding stage and very encouraged by the overall response to the announcement of the Strategic Review Process.
  • The Board did, however, encourage LifeSci to join the ongoing strategic review process.
  • Diffusion Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapies to enhance the bodys ability to deliver oxygen to areas where it is needed most.

Data Discovery Market to Witness CAGR of 17% (2021-2027) on account of Increasing Investment in Data Privacy| UnivDatos Market Insights

Retrieved on: 
Friday, November 4, 2022
Cloud, Microsoft, SAS Institute Inc v World Programming Ltd, HIPAA, Health care, CCPA, Growth, Investment, GDPR, California Consumer Privacy Act, CAGR, Tableau Software, IOT, BFSI, Telecommunication, Component, Health Insurance Portability and Accountability Act, Data analysis, Software, Organization, Adoption, Data science, ISO, COVID-19, General Data Protection Regulation, Social media, Government, USD, Data mining, Qlik, Accountability Act, Privacy, Efficiency, Pharmaceutical industry, Online shopping, Nectar Lifesciences, Coronavirus, NOIDA, Shopify

The Data Discovery market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.

Key Points: 
  • The Data Discovery market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.
  • The Data Discovery market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth.
  • Furthermore, this statistical market research repository examines and estimates the Data Discovery market at the global and regional levels.
  • The growing prominence of the IoT devices, increasing social media users and E-commerce customers are expected to drive the data discovery market.

Data Discovery Market to Witness CAGR of 17% (2021-2027) on account of Increasing Investment in Data Privacy| UnivDatos Market Insights

Retrieved on: 
Friday, November 4, 2022
Cloud, Microsoft, SAS Institute Inc v World Programming Ltd, HIPAA, Health care, CCPA, Growth, Investment, GDPR, California Consumer Privacy Act, CAGR, Tableau Software, IOT, BFSI, Telecommunication, Component, Health Insurance Portability and Accountability Act, Data analysis, Software, Organization, Adoption, Data science, ISO, COVID-19, General Data Protection Regulation, Social media, Government, USD, Data mining, Qlik, Accountability Act, Privacy, Efficiency, Pharmaceutical industry, Online shopping, Nectar Lifesciences, Coronavirus, NOIDA, Shopify

The Data Discovery market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.

Key Points: 
  • The Data Discovery market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.
  • The Data Discovery market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth.
  • Furthermore, this statistical market research repository examines and estimates the Data Discovery market at the global and regional levels.
  • The growing prominence of the IoT devices, increasing social media users and E-commerce customers are expected to drive the data discovery market.

HYTN Initiates Sale of Cannabis Products in Quebec Through Agreement With Rose

Retrieved on: 
Monday, October 24, 2022
Cannabis, Sale, Growth, Nectar Lifesciences, ROSE, Agreement, Partnership, Company, Marketing, CSE, CEO, QC, GLOBE, SQDC, Drug

VANCOUVER, British Columbia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (HYTN or the Company) (CSE: HYTN) is pleased to announce that its wholly owned subsidiary, HYTN Cannabis Inc., has entered into a sales, distribution and marketing agreement (the Agreement) with Rose LifeScience Inc. (Rose ScienceVie) (Rose), a leading supplier of cannabis products in Quebec.

Key Points: 
  • VANCOUVER, British Columbia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (HYTN or the Company) (CSE: HYTN) is pleased to announce that its wholly owned subsidiary, HYTN Cannabis Inc., has entered into a sales, distribution and marketing agreement (the Agreement) with Rose LifeScience Inc. (Rose ScienceVie) (Rose), a leading supplier of cannabis products in Quebec.
  • The Agreement provides a path for HYTN to sell its products, through Rose, to la Socit qubcoise du cannabis (the SQDC) and supports the Companys goal of delivering its consistent, natural and delicious cannabis products featuring Elevation Technology to every province and territory in Canada.
  • Jason Broome, HYTN Chief Operating Officer, stated, Quebec is a critical market for HYTNs cannabis beverages.
  • Pursuant to the Agreement, all revenue from orders of HYTNs cannabis products will flow from the SQDC through Rose to HYTN.

LifeSci Partners Launches LifeSci Events, Life Sciences-focused Corporate Event Planning Agency

Retrieved on: 
Monday, August 1, 2022
KOL, Nectar Lifesciences, Research, Program, Corporation, GLOBE, Technology, Industry, Patient, Public relations

NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- LifeSci Partners, a life science focused consultancy, announced today the launch of LifeSci Events, which supports life sciences companies with turnkey strategic corporate event planning services.

Key Points: 
  • NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- LifeSci Partners, a life science focused consultancy, announced today the launch of LifeSci Events, which supports life sciences companies with turnkey strategic corporate event planning services.
  • LifeSci Events will leverage its existing strong relationships in the medical, scientific, regulatory, and reimbursement communities to seamlessly facilitate the event planning process.
  • In addition, LifeSci Events will utilize LifeSci Partners extensive experience marketing companies to top-tier life sciences-focused institutional investors and research analysts to maximize visibility and engagement with Wall St. around all appropriate events.
  • The new division adds strategic event planning services to the fully integrated offerings of LifeSci Partners .

AIM Stockholder Full Value Committee Announces Director Nominations for AIM Annual Meeting and Confirms Intent to Proceed with Proxy Solicitation

Retrieved on: 
Thursday, July 21, 2022
U.S. FDA, AIM, Rockwell Medical, Marketing, Baxter International, Wall Street, Sun Pharma, Company, Security (finance), Mitchell, Douglas v. U.S. District Court ex rel Talk America, LLC, ThinkEquity, Securities and Exchange Commission (Nigeria), NO, ASFV, Canaccord Genuity, Bank, Partner, KOL, Nectar Lifesciences, Biotechnology, List of life sciences, Notice, GLOBE, CEO, SEC, VP, Board, Participation, Director, Exercise, FDA, Rintatolimod, District court, Founder, UPON, WHEN, Bank of America, NASDAQ, THE, Principal, Drug development, Patient, Health, OTCQX, Holding company, Management, Pharmaceutical industry

Notwithstanding meritless claims to the contrary by AIM, the Notice is valid and complied with AIMs bylaws.

Key Points: 
  • Notwithstanding meritless claims to the contrary by AIM, the Notice is valid and complied with AIMs bylaws.
  • As such, the AIM Stockholder Full Value Committee intends to file a preliminary proxy statement with the SEC in due course and solicit proxies for the election of Mr. Chioini and Mr. Rice at AIMs annual meeting of stockholders.
  • IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.
  • The participants in the proxy solicitation are expected each to be member of the ASFV Committee and River Rock Advisors LLC (collectively, the Participants).